Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 655066 dose-finding placebo-controlled phase 2 study in ankylosing spondylitis
NL-OMON40442Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of risankizumab in ankylosing spondylitis (AS) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: ASAS 40 response. Started Jul 2014; status: active, not recruiting.
02
Drugs
risankizumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NL-OMON40442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40442.